BioSpace News Archive

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Today, the U.S. Food and Drug Administration issued emergency use authorization (EUA) to launch the GetMyDNA COVID-19 Test Home Collection Kit DTC, which is now available for broad use for both symptomatic and asymptomatic individuals with no prescription required.

Under the agreement, DotBio’s Hong Kong subsidiary, DotBioHK, is responsible for generating multiple multi-valent and/or bi-specific stabilized and humanized single-domain antibody candidates for various targets using DotBio’s proprietary DotBody technology.

Kaiser Permanente research finds older adults vaccinated with pneumococcal conjugate vaccine received some protection against COVID-19

Munich Re Life US is pleased to help fund two critical American Cancer Society Research Scholar Grants that focus on increasing the survival rates amongst breast cancer patients.

Scitara Corporation, a pioneer in digital transformation and IoLT and an emerging leader in delivering data connectivity to scientific laboratories, today announced version 1.0 of its Scitara Digital Lab Exchange (DLX™) SaaS cloud platform which dramatically advances the state of data connectivity and automation in scientific laboratories.

La Jolla Institute for Immunology (LJI), one of the leading research organizations dedicated to studying the immune system announced today that it has signed a licensing agreement with Leinco Technologies, Inc., a premier developer and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates.

As home and office space merged during the pandemic, many people said they spent more time in front of screens and suffered because of it.

Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced it has received Notice of Allowance from the European Patent Office (EPO) combining minimum intensity of nerve stimulation (MIS) and real-time injection pressure (IP) monitoring utilizing Milestone’s CompuFlo®

Pivotal Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Chemotherapy in Patients with Advanced Endometrial Cancer to be Presented During Plenary Session Additional Plenary Session to Include Investigational Data on Farletuzumab Combination with Carboplatin in Patients with Low CA125 Platinum-Sensitive Ovarian Cancer